Search PubMed⌕ Search

Biomedical subjects

Iu B Belousov

Publications and source records attributed to Iu B Belousov.

At least 19 recordsLinked to original sources
PubMed2006

[Comparative efficacy and safety of contemporary Angiotensin converting enzyme inhibitors moexipril and spirapril in women with postmenopausal metabolic syndrome].

Moexipril (7.4-15 mg/day) was given to 34, spirapril (3-6 mg/day) -- to 18 postmenopausal women with hypertension and metabolic syndrome for 16 weeks. Hydrochlorthiazide was added when therapy was not sufficiently effective. Both angiotensin converting enzyme inhibitors had similar hypotensive activity: blood pressure normalized in 71 and 61% of moexipril and spirapril treated women, respectively. Both drugs promoted normalization of metabolism of lipid (lowering of levels of cholesterol, atherogenic lipoproteins and triglycerides) and carbohydrates (lowering of hyperinsulinemia). Patients with postmenopausal metabolic syndrome had elevation of leptin level up to 27.5+/-5.5 pg/ml. Moexipril and spirapril caused lowering of elevated levels of leptin. These drugs did not affect levels of sex hormones. They exerted vasoprotective (normalization of endothelium dependent and independent vasodilatation) and nephroprotective (attenuation and normalization of microalbuminuria) effects. Thus spirapril and moexipril are effective in treatment of hypertension in patients with postmenopausal metabolic syndrome.

Angiotensin-Converting Enzyme Inhibitors↗
PubMed2006

[Hypotensive, organoprotective, and metabolic effects of Angiotensin converting enzyme inhibitor moexipril in women with postmenopausal syndrome].

Hypotensive, organoprotective, and metabolic effects of angiotensin converting enzyme inhibitor moexipril (7.5-15 mg/day for 16 weeks) with or without combination with hydrochlorothiazide was studied in 34 women (mean age 59.6+/-1.6 years) with postmenopausal metabolic syndrome and hypertension. Thirty four women had dyslipidemia, 22 -- disturbances of carbohydrate metabolism, 18 -- obesity (mean body mass index 31.1+/-0.8 kg/m(2)). Treatment was associated with lowering of office systolic(-20.1%) and diastolic (-17.4%) blood pressure (BP). Target BP (140/90 mm Hg) was achieved in 27 patients. There also occurred significant lowering of mean 24 hour, diurnal, and nocturnal systolic and diastolic BP (p<0.05), significant changes of values of systolic and diastolic BP time indexes, normalization of which was observed both during day and night hours. Significant lowering of total cholesterol (-11.6%, p<0.05), low density lipoprotein cholesterol (-16.3%, p<0.02), and in patients with obesity of triglycerides (-27%, p<0.02) was revealed at the background of treatment with moexipril. In a group as a whole we observed significant lowering of excretion of albumins and b2-microglobulin; most pronounced antiproteinuretic effect was noted in patients with high microproteinuria and obesity. Vasodilating function of vessels improved in all patients with postmenopausal metabolic syndrome, mainly at the account of increment of endothelium dependent vasodilation and normalization of index of vasodilatation.

Adult↗
PubMed2006

[Ivabradine--the first selective and specific I(f) inhibitor, novel preparation for treatment of stable angina].

Results of large epidemiological studies allowed to establish that heart rate (HR) is an independent risk factor, elevating rates of total, cardiovascular and sudden mortality. Ivabradine bounds specifically with f channels of sinus node cells providing HR lowering. In experiments with the use of the method of registration of transmembrane currents in cells of sinoatrial node it was revealed that Ivabradine blocks f-channels in a dose-dependent manner. Due to specific action on sinus node and selective suppression of I(f)-currents ivabradine causes dose dependent decrease of HR both at rest and maximal physical exercise without changes of mean blood pressure. It was shown in 3 large clinical studies that Ivabradine together with favorable tolerability profile possesses pronounced antianginal and anti-ischemic efficacy which is at least the same as efficacy of currently available drugs for the treatment of angina beta-adrenoblockers and calcium antagonists. Firstly this confirms clinical significance of concept of specific and selective inhibition of I(f) ionic current in the treatment of patients with ischemic heart disease and stable angina. Secondly this allows to consider the preparation as alternative to available antianginal drugs in case of the presence of contraindications to them or development of side effects at the background of standard therapy.

Angina Pectoris↗
PubMed2005

[Biological resonance as a possible mechanism of an ototoxic action of aminoglycoside antibiotics].

Literature data on mechanisms of an ototoxic action of aminoglycoside antibiotics (AGA) doubt pharmacological basis of this phenomenon. It is suggested that the above ototoxicity may result from wave interference between wave processes in the inner ear and electromagnetic AGA field. The interaction is primary, informative and initiate apoptosis of the hair cells of the internal ear. The model experiment showed feasibility of frequency-resonance interaction between AGA and biopreparations of the acoustic apparatus of the animals.

Aminoglycosides↗
PubMed2005

[Effect of long-term therapy with contemporary drugs on diastolic cardiac function in patients with chronic heart failure].

Bisoprolol, carvedilol, enalapril are widely used for the treatment of patients with chronic heart failure. Definite role in the treatment of these patients is also played by angiotensin-II receptor blockers. Diastolic left ventricular function is widely spread among patients with chronic heart failure and its important value for prognosis has been demonstrated. However effect of modern drugs used for the treatment of chronic heart failure has been poorly studied. We assessed effects of enalapril, its combination with bisoprolol, carvedilol, and irbesartan on parameters of diastolic function in a randomized prospective controlled study on 84 patients with NYHA class III-IV heart failure and left ventricular ejection fraction <40%. It has been shown that left ventricular dysfunction is highly prevalent in patients with chronic heart failure and that differentiated approach to the choice of a drug for the treatment of chronic heart failure requires consideration of the type of diastolic dysfunction.

Adrenergic beta-Antagonists↗
PubMed2005

[Confirmation of safety and therapeutic effect of betaxolol in the treatment of mild and moderate hypertension in general medical practice].

Data on office blood pressure (BP) and pulse rate as well as information on adverse effects were collected from 148 patients with mild and moderate hypertension during 12 week treatment with long acting lipophilic selective beta-adrenoreceptor blocker betaxolol (20 mg/day). BP normalization was achieved in 72.5% and in 16.8% of patients BP was lowered more than 10% without achievement of target values. Pulse rate lowering by more than 15 beats/min occurred in 40.3% of patients. Combined therapy was required in 15.2% of patients. Adverse effects specific for the class of beta-adrenoblockers caused cessation of betaxolol therapy in 3 patients. The drug was found ineffective in 4 patients (2.7%). Thus we confirmed high clinical efficacy and good safety and tolerability of betaxolol in patients with mild and moderate hypertension.

Adrenergic beta-Antagonists↗
PubMed2005

[Moexipril influence on quality of life in postmenopausal women with arterial hypertension].

AIM: To evaluate a hypotensive effect and metabolic neutrality and safety of ACE inhibitor moexipril in postmenopausal women with arterial hypertension (AH), influence on quality of life. MATERIAL AND METHODS: Thirty two hypertensive postmenopausal women (age 63.1 +/- 0.8 years) received moexipril for 4 months. The history of AH was 10.4 +/- 2.3 years, on the average. After a free of drugs week moexipril was given in a dose 7.5 mg/day with titration to 15 mg in 2 weeks and addition (if the target pressure was not achieved) of hydrochlorothiaside in a dose 12.5 mg. The examination included 24-h monitoring of blood pressure, estimation of microalbuminuria (MAU), endothelial function and blood biochemistry. Initially and after 4 weeks of the treatment quality of life was assessed (scales SF-36 and EuroQol). RESULTS: The initial level of office BP was 164.33/94.50 mm Hg, in 3 months a target level was achieved (136/84 mm Hg). It persisted for the next month. Moexipril corrected endothelial function and vascular elasticity in all the patients. MAU fell from 28.28 to 8.10 mg/l. Quality of life improved. Lipid and carbohydrate changes were not registered. CONCLUSION: Moexipril has a hypotensive and nephroprotective effects, improves endothelial function and quality of life in hypertensive postmenopausal women.

Angiotensin-Converting Enzyme Inhibitors↗
PubMed2004

[Selective microproteinuria as a marker of incipient renal impairment in patients with hypertension].

Incidence of chronic renal failure has a worldwide tendency to growth. Hypertension occupies an important place among causes of this upward trend. That is why in patients with hypertension and incipient changes of the kidneys it seems most appropriate to use antihypertensive drugs with renoprotective properties. Early treatment with these drugs enables most effective lowering of risk of renal failure development and thus has a potential to prolong life of a patient. Selective microproteinuria is considered to be a marker of incipient renal impairement. Among groups of antihypertensive agents angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium antagonists, beta-blockers, and diuretics have proven renoprotective properties.

Adrenergic beta-Antagonists↗
PubMed2004

[Cost-effect estimation of dopamine agonist (mirapex) application in patients with Parkinson's disease].

Parkinson's disease is a neurodegenerative disorder with a growing social significance. Currently, dopamine agonists are considered as first-line medication used before levodopa treatment. High cost of dopamine agonists makes it necessary to estimate their cost efficacy by means of pharmacoeconomical studies. We studied efficacy of mirapex evaluated by UPDRS and PDQ-39 scores before and after 1-year treatment in 44 patients with Parkinson's disease: 18 patients non-pretreated with levodopa and 26 patients pretreated with levodopa. Treatment cost was estimated separately for two patients groups with subsequent cost-effectiveness analysis. Early use of mirapex as a dopamine agonist for patients non-treated with levodopa seems to be beneficial from clinical well as from pharmacieconomical points of view.

Cost-Benefit Analysis↗